Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug ...
The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...
InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...
InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...
The FDA has approved Medtronic plc's (NYSE: MDT) InterStim X, the next generation of the InterStim portfolio's recharge-free device. InterStim systems deliver sacral neuromodulation (SNM) therapy.
MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results